Cathie Wood’s ARK buys Meta stock, sells Teradyne and Palantir

Cathie Wood's ARK ETF reported its daily trades on Thursday, October 22, 2026, showcasing strategic shifts in various industries. The most notable transaction was the acquisition of 38,110 shares of Meta Platforms, Inc. (NASDAQ:META) valued at $26,582,487, spread across ARKK, ARKW, and ARKF ETFs, reflecting confidence in the company's future.

ARK sold 57,444 shares of Teradyne, Inc. (NASDAQ:TER) through ARKK, totaling $19,846,327, continuing its pattern of divestment from Teradyne. The firm also sold 23,020 shares of Block, Inc. (NYSE:XYZ) via ARKW, valued at $1,800,394, aligning with its recent reduction in Block holdings. ARK increased its stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB) by buying 354,696 shares across ARKK and ARKG, totaling $759,049, indicating optimism in the biotech sector.

Additionally, ARK boosted its position in Scribe Therapeutics Inc (SCTX) with a purchase of 99,254 shares for $1,915,602, continuing its trend of accumulating shares in this company. Conversely, ARK reduced its Palantir Technologies Inc. (NYSE:PLTR) position by selling 7,936 shares through ARKF, amounting to $1,600,849, part of an ongoing strategic adjustment.

Other transactions included the purchase of 35,377 shares of Freenome, Inc. (FRNM) and 6,604 shares of Iambic Therapeutics, Inc. (IAM) by ARKG, valued at $495,631 and $104,343 respectively. Finally, ARK divested 33,793 shares of Roblox Corporation (NYSE:RBLX) through ARKW for $1,775,822, and sold 5,397 shares of Shopify Inc. (NYSE:SHOP) for $940,643.

These moves highlight ARK's diversified investment approach, combining high-growth technology firms with promising biotech ventures while selectively reducing positions in other sectors. Investors will be watching closely to see how these actions align with ARK's strategic vision and market forecasts.